MaxCyte, Inc. (MXCT)
NASDAQ: MXCT · Real-Time Price · USD
0.6998
-0.0170 (-2.37%)
Mar 27, 2026, 10:17 AM EDT - Market open
MaxCyte Revenue
In the year 2025, MaxCyte had annual revenue of $33.03M, down -14.50%. MaxCyte had revenue of $7.30M in the quarter ending December 31, 2025, a decrease of -16.02%.
Revenue (ttm)
$33.03M
Revenue Growth
-14.50%
P/S Ratio
2.32
Revenue / Employee
$362,923
Employees
91
Market Cap
74.78M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 33.03M | -5.60M | -14.50% |
| Dec 31, 2024 | 38.63M | -2.66M | -6.44% |
| Dec 31, 2023 | 41.29M | -2.97M | -6.72% |
| Dec 31, 2022 | 44.26M | 10.37M | 30.59% |
| Dec 31, 2021 | 33.89M | 7.73M | 29.52% |
| Dec 31, 2020 | 26.17M | 4.55M | 21.04% |
| Dec 31, 2019 | 21.62M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Treace Medical Concepts | 212.69M |
| Neuronetics | 149.16M |
| Xtant Medical Holdings | 133.08M |
| Outset Medical | 119.48M |
| LENSAR | 59.14M |
| Baird Medical Investment Holdings | 31.86M |
| Sensus Healthcare | 27.48M |
| QT Imaging Holdings | 18.93M |
MXCT News
- 2 days ago - MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance - GlobeNewsWire
- 4 days ago - MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer - GlobeNewsWire
- 4 weeks ago - MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery - GlobeNewsWire
- 4 weeks ago - MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026 - GlobeNewsWire
- 2 months ago - MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 4 months ago - Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO - Business Wire
- 4 months ago - MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript - Seeking Alpha